Acute Kidney Injury
Conditions
Keywords
dexmedetomidine, pharmacokinetics, critical illness, continuous renal replacement therapy
Brief summary
The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.
Detailed description
Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.
Interventions
DRUGDexmedetomidine
Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
Sponsors
Helsinki University Central Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 * Clinical need for sedation * Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures)
Exclusion criteria
* Severe bradycardia (HR \< 50/min) * AV conduction block II-III (unless pacemaker installed) * Severe hepatic impairment (bilirubin \> 101 umol/l) * Pregnancy or lactation * Age \< 18
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dexmedetomidine clearance by continuous venovenous hemodialysis | 10 hours from the start of the dexmedetomidine infusion |
Countries
Finland
Contacts
Primary ContactKirsi-Maija Kaukonen, MD, PhD
Backup ContactSuvi Vaara, MD
Outcome results
None listed